18257 Secukinumab demonstrates sustained effectiveness and safety in patients with moderate to severe plaque psoriasis: 30-month follow-up data from the PURE registry

Abstract

Introduction: PURE, an international, prospective, observational study from Canada and Latin America, assesses real-world safety and effectiveness of secukinumab in patients with moderate to severe psoriasis (PsO) vs other approved therapies. This abstract describes clinical outcomes from an interim analysis in secukinumab-treated group, stratified by prior biologic experience over 30 months (M30) of treatment.